Changqing Li

Dr. Changqing Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
HTHao Tang
Hao Tang
JLJiani Li
Jiani Li
QZQinxiang Zhou
Qinxiang Zhou
SLSheng Li
Sheng Li
CXChenchen Xie
Chenchen Xie
CLChangqing Li
Changqing Li
Cumulative evidence suggests that pyroptosis, a new sort of programmed cell death, is closely related to cerebral ischemia/reperfusion (I/R) injury. Our previous studies have testified that vagus nerve stimulation (VNS) was involved in many different neuroprotective and neuroplasticity pathways via α7 nicotinic acetylcholine receptor (α7nAchR), a vital node of the cholinergic anti-inflammatory pathway during cerebral I/R injury. We aimed to determine the neuroprotective effects of VNS through α7nAchR-mediated inhibition of pyroptosis. Focal cerebral ischemic stroke rat models were obtained by middle cerebral artery occlusion for 120 min. Expression of the NLRP3 inflammasome was evaluated using western blotting and immunofluorescence (IF) staining. The neurological deficit score, infarct volume, TUNEL staining findings, transmission electron microscopy findings, and expression of inflammatory cytokines were assessed 3 days after I/R injury. Our findings suggested that the protein expression levels of NLRP3, GSDMD-N, cleaved caspase-1, and ASC gradually increased until they peaked on day 3 after I/R injury. VNS inhibited the expression of pyroptosis-related molecules and decreased the number of pyroptotic cells and membrane pores. Administration of α7nAchR-antagonist and agonist helped in further assessment of the role of α7nAchR in pyroptosis. α7nAchR-agonist mimicked VNS’s neuroprotective effects on the improvement of neurological deficits, the reduction of infarct volumes, and the inhibition of neuronal pyroptosis after cerebral I/R injury. Conversely, the neuroprotection provided by VNS could be reversed by the administration of α7nAchR-antagonist. In conclusion, VNS-induced neuroprotection via inhibition of neuronal pyroptosis was α7nAchR-dependent, highlighting the pivotal role of α7nAChR in suppressing cellular pyroptosis and neuroinflammation. These findings may allow a better understanding of treatment principles for cerebral I/R injury.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JLJiani Li
Jiani Li
KZKeming Zhang
Keming Zhang
QZQinbin Zhang
Qinbin Zhang
XZXueling Zhou
Xueling Zhou
LWLan Wen
Lan Wen
CLChangqing Li
Changqing Li
Background. Neoangiogenesis after cerebral ischemia in mammals is insufficient to restore neurological function, illustrating the need to design better strategies for improving outcomes. Our previous study has suggested that transcutaneous auricular vagus nerve stimulation (ta‐VNS) induced angiogenesis and improved neurological functions in a rat model of cerebral ischemia/reperfusion (I/R) injury. However, the mechanisms involved need further exploration. Peroxisome proliferator‐activated receptor‐γ (PPAR‐γ), well known as a ligand‐modulated nuclear transcription factor, plays a crucial role in the regulation of cerebrovascular structure and function. Hence, the present study was designed to explore the role of PPAR‐γ in ta‐VNS‐mediated angiogenesis and uncover the possible molecular mechanisms against ischemic stroke. Methods. Adult male Sprague–Dawley rats were transfected with either PPAR‐γ small interfering RNA (siRNA) or lentiviral vector without siRNA prior to surgery and subsequently received ta‐VNS treatment. The expression and localization of PPAR‐γ in the ischemic boundary after ta‐VNS treatment were examined. Subsequently, neurological deficit scores, neuronal damage, and infarct volume were all evaluated. Additionally, microvessel density, endothelial cell proliferation condition, and the expression of angiogenesis‐related molecules in the peri‐infarct cortex were measured. Results. We found that the expression of PPAR‐γ in the peri‐infarct cortex increased at 14 d and reached normal levels at 28 d after reperfusion. Ta‐VNS treatment further upregulated PPAR‐γ expression in the ischemic cortex. PPAR‐γ was mainly expressed in neurons and astrocytes. Furthermore, ta‐VNS‐treated I/R rats showed better neurobehavioral recovery, alleviated neuronal injury, reduced infarct volume, and increased angiogenesis, as indicated by the elevated levels of brain‐derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), and phosphorylated endothelial nitric oxide synthase (P‐eNOS). Surprisingly, the beneficial effects of ta‐VNS were weakened after PPAR‐γ silencing. Conclusions. Our results suggest that PPAR‐γ is a potential mediator of ta‐VNS‐induced angiogenesis and neuroprotection against cerebral I/R injury.

16 August 2022 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
CXChenchen Xie
Chenchen Xie
HTHao Tang
Hao Tang
GLGang Liu
Gang Liu
CLChangqing Li
Changqing Li
Backgroud: Vascular dementia is the second most common cause of dementia after Alzheimer’s disease, accounting for an estimated 15% of cases. Recently, Epimedium has attracted great attention for its potential neuroprotective benefit. However, the direct role and mechanism of Epimedium on vascular dementia still lack systematic research. To systematically explore the possible pharmacological mechanism of Epimedium for the treatment of vascular dementia, network pharmacology, molecular docking, combined with experiment validation were conducted.Methods: The bioactive compounds and targets of Epimedium were obtained from the TCMSP database. The potential targets of vascular dementia were identified from the DrugBank, OMIM, Genecards, Therapeutic Target Database, and DisGeNET databases. GO and KEGG pathway analyses were performed. Molecular docking was applied to validate the interaction between active components and hub targets. The bilateral common carotid artery occlusion (BCCAO) method was used for construction of a vascular dementia model in mice. The effects of Epimedium on learning and memory ability were examined by behavioral tests. The mechanisms of the cerebral protective effects of Epimedium were evaluated by WB, RT-PCR, and immunofluorescence.Results: A total of 23 Epimedium active ingredients, and 71 intersecting targets of Epimedium against vascular dementia were obtained. The top five hub targets AKT1, TNF, IL1β, IL6, and MMP9 were identified, and molecular docking showed good binding. GO enrichment showed a total of 602 enrichment results, with 458 (80.56%) key targets mainly focused on biological processes (BP). The response to hypoxia, positive regulation of nitric oxide biosynthetic process, aging, inflammatory response, cellular response to lipopolysaccharide, negative regulation of apoptotic process were well ranked. KEGG pathway enrichment analysis identified the TNF signaling pathway as an important pathway, with the MAPK/extracellular signal-regulated kinase (ERK) and NF-κB signaling pathways as the key pathways involved. Consistently, in vivo experiments showed that Epimedium treatment improved learning and memory functions in mice with vascular dementia. In addition, Epimedium attenuated the activation of microglia and astrocytes in the hippocampal region after BCCAO. RT-qPCR and Western blot analysis showed that Epimedium not only affected the expression of AKT, TNF, IL1β, IL6, and MMP9, but also suppressed the TNF signaling pathway.Conclusion: Epimedium may exert a protective effect against vascular dementia through the alleviation of oxidative stress, neuroinflammation, BBB dysfunction, apoptosis through TNF signaling pathway. This study explored the mechanism of Epimedium on vascular dementia systematically through network pharmacological and in vivo experiment approach, which provides insight into the treatment of vascular dementia.

6 December 2024 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
XZXuemin Zhong
Xuemin Zhong
JMJinxuan Ming
Jinxuan Ming
CLChangqing Li
Changqing Li
The relationship between depression and dyslipidemia remains controversial, with inconsistent findings across studies. This study aimed to investigate the association between blood lipid levels and depression using data from the National Health and Nutrition Examination Survey (NHANES) spanning from 2007 to 2018. This cross-sectional study included 12,819 adult participants from NHANES. Depression was assessed using a nine-item depression screening instrument. Serum lipid levels, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG), were measured using Roche modular P and Roche Cobas 6000 chemistry analyzers. Survey-weighted multiple logistic regression was used to assess the relationships between serum lipid levels and depression. We observed a statistically significant negative association between HDL levels and depression (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.58–0.90). After adjustments for covariates, HDL-C, TG, and the triglyceride glucose (TyG) index showed significant associations with depression (ORs: 0.66, 1.08, and 1.01, respectively). A linear correlation was observed between HDL-C levels and depression (P < 0.01), while TG levels and the TyG index exhibited nonlinear associations (p < 0.01 and p < 0.05, respectively). No significant positive associations were observed between increased TC or LDL-C levels and the risk of depression. High HDL-C levels were negatively associated with depression, while TG levels and the TyG index were positively associated with depression. Clinical attention should be given to the detection of lipid levels in patients with depression.

1 February 2021 in Neuroscience Letters
Verified
Journal Article
Closed access
XTXiao-Dan Tan
Xiao-Dan Tan
BLBin Liu
Bin Liu
YJYing Jiang
Ying Jiang
HYHong-Jun Yu
Hong-Jun Yu
CLChangqing Li
Changqing Li

16 July 2024 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
MGMeng Guo
Meng Guo
CYChengsong Yue
Chengsong Yue
JYJie Yang
Jie Yang
JHJinrong Hu
Jinrong Hu
CGChangwei Guo
Changwei Guo
CLChangqing Li
Changqing Li
Background Endovascular treatment (EVT) is a well-established approach for acute ischemic stroke. Whether bridging intravenous thrombolysis (IVT) before EVT confers any benefits remains uncertain. The objective of the study was to compare the efficacy and safety of direct EVT with or without bridging IVT in patients with acute basilar artery occlusion (BAO). Methods This multicenter cohort study enrolled 647 patients with acute BAO who underwent either bridging IVT before EVT or direct EVT from the BASILAR registry. The primary outcome was an independent functional outcome measured by the modified Rankin Scale (mRS) score of 0–2. Secondary outcomes included excellent functional outcome (mRS 0–1), favorable functional outcome (mRS 0–3), and mortality rate at 90 days, as well as symptomatic intracranial hemorrhage (sICH), and successful reperfusion between the two treatment groups. Results Direct EVT and bridging IVT before EVT exhibited similar primary outcomes (27.3% vs 27.7%, respectively) and distributions of mRS scores at 90 days. Moreover, rates of sICH and 90-day mortality were not significantly different between the two groups (7.3% vs 6.0%, adjusted OR (aOR) 0.79, 95% CI 0.34 to 1.86, P=0.84 for sICH; 46.8% vs 43.7%, aOR 0.86, 95% CI 0.54 to 1.38, P=0.53 for mortality). Conclusions Among patients with acute BAO, functional outcomes were similar between those treated with bridging IVT before EVT and those treated with direct EVT, and there was no difference between the two groups in terms of sICH and mortality rates.